^
Association details:
| Biomarker: | EGFR L747P |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors
Published date:
02/11/2022
Excerpt:
A total of five metastatic NSCLC patients with p.L747P mutation were included in the final analysis. Patients treated with second-generation (2G) TKI afatinib achieved numerically longer progression-free survival (range 2.4-8.5 months) than that with first-generation (1G, range 1.4-5.5 months) or third-generation (3G, range 1.6-7.5 months) TKIs...the uncommon p.L747P mutation leads to a worse response to 1G EGFR TKIs when compared with the classic EGFR exon 19 deletions. Afatinib shows better binding affinity and antitumor activity compared with osimertinib for p.L747P mutation.
DOI:
10.3389/fonc.2022.843299
Source:
Title:
P50.07 - Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations in Chinese Population
Published date:
08/18/2021
Excerpt:
...TTF was 15.0, 11.7, and 16.6 months in patients with G719X, S768I, and L861Q mutations, respectively. In patients with the rare uncommon mutation, median TTF was 10.0 months and the ORR was 50.0%. Afatinib demonstrated clinical activity across a set type of specific rare mutations, including EGFR L747P, A767_V769dup, and L833V/H835L, with a case of TTF > 1 year.
Source:
Title:
Molecular Characteristics and Response to EGFR TKIs of EGFR L747 Position Mutation in Lung Cancer Patients.
Published date:
01/12/2021
Excerpt:
...patients treated with EGFR TKIs, three EGFR L747P patients achieved partial response through afatinib treatment...EGFR L747 mutations account for 0.4% in EGFR-mutated NSCLC patients and EGFR L747P/S/V were common mutations identified. EGFR L747P might exert superior sensitivity to afatinib treatment...
